Contact, publication, and social network information about Harvard faculty and fellows. Harvard Catalyst Profiles
Keywords
Last Name
Institution

Kenneth Alan Bauer, M.D.

TitleProfessor of Medicine
InstitutionBeth Israel Deaconess Medical Center
DepartmentMedicine
AddressBeth Israel Deaconess Med Ctr
Hemo/Thrombosis - RW 663
330 Brookline Ave
Boston MA 02215
Phone617/667-2174
Fax617/363-5592

 Bibliographic 
 selected publications
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
List All   |   Timeline
  1. Lopaciuk S, Windyga J, Watala CW, Bykowska K, Pietrucha T, Kwiecinski H, Czlonkowska A, Kuczynska-Zardzewialy A, Jackson AA, Carew JA, Bauer KA. Polymorphisms in the factor VII gene and ischemic stroke in young adults. Blood Coagul Fibrinolysis. 2010 Jul; 21(5):442-7.
    View in: PubMed
  2. Bauer KA. Thrombophilia evaluation: the value of testing relatives. Clin Adv Hematol Oncol. 2010 Apr; 8(4):229-31.
    View in: PubMed
  3. Arepally G, Bauer KA, Bhatt DL, Merli GJ, Naccarelli GV, Carter RD, Karcher RB, Berry CA, Keaton KL, Stowell SA. The use of antithrombotic therapies in the prevention and treatment of arterial and venous thrombosis: a survey of current knowledge and practice supporting the need for clinical education. Crit Pathw Cardiol. 2010 Mar; 9(1):41-8.
    View in: PubMed
  4. Bauer KA. New oral anticoagulants in development: potential for improved safety profiles. Rev Neurol Dis. 2010; 7(1):1-8.
    View in: PubMed
  5. Mantha S, Bauer KA, Zwicker JI. Low molecular weight heparin to achieve live birth following unexplained pregnancy loss: a systematic review. J Thromb Haemost. 2010 Feb; 8(2):263-8.
    View in: PubMed
  6. Zwicker JI, Liebman HA, Neuberg D, Lacroix R, Bauer KA, Furie BC, Furie B. Tumor-derived tissue factor-bearing microparticles are associated with venous thromboembolic events in malignancy. Clin Cancer Res. 2009 Nov 15; 15(22):6830-40.
    View in: PubMed
  7. Ireland HA, Cooper JA, Drenos F, Acharya J, Mitchell JP, Bauer KA, Morrissey JH, Esnouf MP, Humphries SE. FVII, FVIIa, and downstream markers of extrinsic pathway activation differ by EPCR Ser219Gly variant in healthy men. Arterioscler Thromb Vasc Biol. 2009 Nov; 29(11):1968-74.
    View in: PubMed
  8. Turpie AG, Lassen MR, Davidson BL, Bauer KA, Gent M, Kwong LM, Cushner FD, Lotke PA, Berkowitz SD, Bandel TJ, Benson A, Misselwitz F, Fisher WD. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet. 2009 May 16; 373(9676):1673-80.
    View in: PubMed
  9. Jackson D, White I, Kostis JB, Wilson AC, Folsom AR, Wu K, Chambless L, Benderly M, Goldbourt U, Willeit J, Kiechl S, Yarnell JW, Sweetnam PM, Elwood PC, Cushman M, Psaty BM, Tracy RP, Tybjaerg-Hansen A, Haverkate F, de Maat MP, Thompson SG, Fowkes FG, Lee AJ, Smith FB, Salomaa V, Harald K, Rasi V, Vahtera E, Jousilahti P, D'Agostino R, Kannel WB, Wilson PW, Tofler G, Levy D, Marchioli R, Valagussa F, Rosengren A, Wilhelmsen L, Lappas G, Eriksson H, Cremer P, Nagel D, Curb JD, Rodriguez B, Yano K, Salonen J, Nyyssönen K, Tuomainen TP, Hedblad B, Engström G, Berglund G, Loewel H, Koenig W, Hense HW, Meade TW, Cooper JA, De Stavola B, Knottenbelt C, Miller GJ, Cooper JA, Bauer KA, Rosenberg RD, Sato S, Kitamura A, Naito Y, Iso H, Salomaa V, Harald K, Rasi V, Vahtera E, Jousilahti P, Palosuo T, Ducimetiere P, Amouyel P, Arveiler D, Evans AE, Ferrieres J, Juhan-Vague I, Bingham A, Schulte H, Assmann G, Cantin B, Lamarche B, Despres JP, Dagenais GR, Tunstall-Pedoe H, Lowe GD, Woodward M, Ben-Shlomo Y, Davey Smith G, Palmieri V, Yeh JL, Meade TW, Rudnicka A, Brennan P, Knottenbelt C, Cooper JA, Ridker P, Rodeghiero F, Tosetto A, Shepherd J, Lowe GD, Ford I, Robertson M, Brunner E, Shipley M, Feskens EJ, Di Angelantonio E, Kaptoge S, Lewington S, Lowe GD, Sarwar N, Thompson SG, Walker M, Watson S, White IR, Wood AM, Danesh J. Systematically missing confounders in individual participant data meta-analysis of observational cohort studies. Stat Med. 2009 Apr 15; 28(8):1218-37.
    View in: PubMed
  10. Bezemer ID, Arellano AR, Tong CH, Rowland CM, Ireland HA, Bauer KA, Catanese J, Reitsma PH, Doggen CJ, Devlin JJ, Rosendaal FR, Bare LA. F9 Malmö, factor IX and deep vein thrombosis. Haematologica. 2009 May; 94(5):693-9.
    View in: PubMed
  11. Turpie AG, Bauer KA, Davidson BL, Fisher WD, Gent M, Huo MH, Sinha U, Gretler DD. A randomized evaluation of betrixaban, an oral factor Xa inhibitor, for prevention of thromboembolic events after total knee replacement (EXPERT). Thromb Haemost. 2009 Jan; 101(1):68-76.
    View in: PubMed
  12. Haspel J, Bauer K, Goehler A, Roberts DH. Long-term anticoagulant therapy for idiopathic pulmonary embolism in the elderly: a decision analysis. Chest. 2009 May; 135(5):1243-51.
    View in: PubMed
  13. Fine G, Bauer K, Al-Mohaya M, Woo SB. Successful treatment of ligneous gingivitis with warfarin. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2009 Jan; 107(1):77-80.
    View in: PubMed
  14. Bauer KA. New anticoagulants. Curr Opin Hematol. 2008 Sep; 15(5):509-15.
    View in: PubMed
  15. Hirsh J, Bauer KA, Donati MB, Gould M, Samama MM, Weitz JI. Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008 Jun; 133(6 Suppl):141S-159S.
    View in: PubMed
  16. Freedman RA, Bauer KA, Neuberg DS, Zwicker JI. Timing of postpartum enoxaparin administration and severe postpartum hemorrhage. Blood Coagul Fibrinolysis. 2008 Jan; 19(1):55-9.
    View in: PubMed
  17. Mueck W, Eriksson BI, Bauer KA, Borris L, Dahl OE, Fisher WD, Gent M, Haas S, Huisman MV, Kakkar AK, Kälebo P, Kwong LM, Misselwitz F, Turpie AG. Population pharmacokinetics and pharmacodynamics of rivaroxaban--an oral, direct factor Xa inhibitor--in patients undergoing major orthopaedic surgery. Clin Pharmacokinet. 2008; 47(3):203-16.
    View in: PubMed
  18. Miller GJ, Ireland HA, Cooper JA, Bauer KA, Morrissey JH, Humphries SE, Esnouf MP. Relationship between markers of activated coagulation, their correlation with inflammation, and association with coronary heart disease (NPHSII). J Thromb Haemost. 2008 Feb; 6(2):259-67.
    View in: PubMed
  19. The Emerging Risk Factors Collaboration: analysis of individual data on lipid, inflammatory and other markers in over 1.1 million participants in 104 prospective studies of cardiovascular diseases. Eur J Epidemiol. 2007; 22(12):839-69.
    View in: PubMed
  20. Govers-Riemslag JW, Smid M, Cooper JA, Bauer KA, Rosenberg RD, Hack CE, Hamulyak K, Spronk HM, Miller GJ, ten Cate H. The plasma kallikrein-kinin system and risk of cardiovascular disease in men. J Thromb Haemost. 2007 Sep; 5(9):1896-903.
    View in: PubMed
  21. Turpie AG, Bauer KA, Caprini JA, Comp PC, Gent M, Muntz JE. Fondaparinux combined with intermittent pneumatic compression vs. intermittent pneumatic compression alone for prevention of venous thromboembolism after abdominal surgery: a randomized, double-blind comparison. J Thromb Haemost. 2007 Sep; 5(9):1854-61.
    View in: PubMed
  22. Bauer KA. Targeted inhibition of coagulation: oral agents show promise in phase III trials. J Thromb Haemost. 2007 Nov; 5(11):2175-7.
    View in: PubMed
  23. Silverstein RL, Bauer KA, Cushman M, Esmon CT, Ershler WB, Tracy RP. Venous thrombosis in the elderly: more questions than answers. Blood. 2007 Nov 1; 110(9):3097-101.
    View in: PubMed
  24. Fisher WD, Eriksson BI, Bauer KA, Borris L, Dahl OE, Gent M, Haas S, Homering M, Huisman MV, Kakkar AK, Kälebo P, Kwong LM, Misselwitz F, Turpie AG. Rivaroxaban for thromboprophylaxis after orthopaedic surgery: pooled analysis of two studies. Thromb Haemost. 2007 Jun; 97(6):931-7.
    View in: PubMed
  25. Kocher O, Cirovic C, Malynn E, Rowland CM, Bare LA, Young BA, Henslee JG, Laffler TG, Huff JB, Kruskall MS, Wong G, Bauer KA. Obstetric complications in patients with hereditary thrombophilia identified using the LCx microparticle enzyme immunoassay: a controlled study of 5,000 patients. Am J Clin Pathol. 2007 Jan; 127(1):68-75.
    View in: PubMed
  26. Cushman M, Glynn RJ, Goldhaber SZ, Moll S, Bauer KA, Deitcher S, Shrivastava S, Ridker PM. Hormonal factors and risk of recurrent venous thrombosis: the prevention of recurrent venous thromboembolism trial. J Thromb Haemost. 2006 Oct; 4(10):2199-203.
    View in: PubMed
  27. Pollak ES, Russell TT, Ptashkin B, Smith-Whitley K, Camire RM, Bauer KA. Asymptomatic factor VII deficiency in African Americans. Am J Clin Pathol. 2006 Jul; 126(1):128-32.
    View in: PubMed
  28. Shrivastava S, Ridker PM, Glynn RJ, Goldhaber SZ, Moll S, Bounameaux H, Bauer KA, Kessler CM, Cushman M. D-dimer, factor VIII coagulant activity, low-intensity warfarin and the risk of recurrent venous thromboembolism. J Thromb Haemost. 2006 Jun; 4(6):1208-14.
    View in: PubMed
  29. Zwicker JI, Peyvandi F, Palla R, Lombardi R, Canciani MT, Cairo A, Ardissino D, Bernardinelli L, Bauer KA, Lawler J, Mannucci P. The thrombospondin-1 N700S polymorphism is associated with early myocardial infarction without altering von Willebrand factor multimer size. Blood. 2006 Aug 15; 108(4):1280-3.
    View in: PubMed
  30. Feinbloom D, Bauer KA. The role of other hemostatic factors in predicting arterial thrombotic events. Arterioscler Thromb Vasc Biol. 2006 Mar; 26(3):e29.
    View in: PubMed
  31. Bauer KA. New anticoagulants: anti IIa vs anti Xa--is one better? J Thromb Thrombolysis. 2006 Feb; 21(1):67-72.
    View in: PubMed
  32. Bauer KA. New anticoagulants. Hematology Am Soc Hematol Educ Program. 2006; 450-6.
    View in: PubMed
  33. Ireland H, Konstantoulas CJ, Cooper JA, Hawe E, Humphries SE, Mather H, Goodall AH, Hogwood J, Juhan-Vague I, Yudkin JS, di Minno G, Margaglione M, Hamsten A, Miller GJ, Bauer KA, Kim YT, Stearns-Kurosawa DJ, Kurosawa S. EPCR Ser219Gly: elevated sEPCR, prothrombin F1+2, risk for coronary heart disease, and increased sEPCR shedding in vitro. Atherosclerosis. 2005 Dec; 183(2):283-92.
    View in: PubMed
  34. Turpie AG, Fisher WD, Bauer KA, Kwong LM, Irwin MW, Kälebo P, Misselwitz F, Gent M. BAY 59-7939: an oral, direct factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging study. J Thromb Haemost. 2005 Nov; 3(11):2479-86.
    View in: PubMed
  35. Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. JAMA. 2005 Oct 12; 294(14):1799-809.
    View in: PubMed
  36. Feinbloom D, Bauer KA. Assessment of hemostatic risk factors in predicting arterial thrombotic events. Arterioscler Thromb Vasc Biol. 2005 Oct; 25(10):2043-53.
    View in: PubMed
  37. Takebe N, Cheng X, Wu S, Bauer K, Goloubeva OG, Fenton RG, Heyman M, Rapoport AP, Badros A, Shaughnessy J, Ross D, Meisenberg B, Tricot G. Phase I clinical trial of the inosine monophosphate dehydrogenase inhibitor mycophenolate mofetil (cellcept) in advanced multiple myeloma patients. Clin Cancer Res. 2004 Dec 15; 10(24):8301-8.
    View in: PubMed
  38. Miller GJ, Bauer KA, Howarth DJ, Cooper JA, Humphries SE, Rosenberg RD. Increased incidence of neoplasia of the digestive tract in men with persistent activation of the coagulant pathway. J Thromb Haemost. 2004 Dec; 2(12):2107-14.
    View in: PubMed
  39. Zwicker JI, Uhl L, Huang WY, Shaz BH, Bauer KA. Thrombosis and ELISA optical density values in hospitalized patients with heparin-induced thrombocytopenia. J Thromb Haemost. 2004 Dec; 2(12):2133-7.
    View in: PubMed
  40. Bauer KA. Role of thrombophilia in deciding on the duration of anticoagulation. Semin Thromb Hemost. 2004 Dec; 30(6):633-7.
    View in: PubMed
  41. Turpie AG, Eriksson BI, Bauer KA, Lassen MR. Fondaparinux. J Am Acad Orthop Surg. 2004 Nov-Dec; 12(6):371-5.
    View in: PubMed
  42. Huang WY, Kruskall MS, Bauer KA, Uhl L, Shaz BH. The use of recombinant activated factor VII in three patients with central nervous system hemorrhages associated with factor VII deficiency. Transfusion. 2004 Nov; 44(11):1562-6.
    View in: PubMed
  43. Lee AY, Gent M, Julian JA, Bauer KA, Eriksson BI, Lassen MR, Turpie AG. Bilateral vs. ipsilateral venography as the primary efficacy outcome measure in thromboprophylaxis clinical trials: a systematic review. J Thromb Haemost. 2004 Oct; 2(10):1752-9.
    View in: PubMed
  44. Bauer KA. Low intensity warfarin: is it clinically useful in venous thromboembolism management? Br J Haematol. 2004 Oct; 127(2):155-8.
    View in: PubMed
  45. Furie KL, Rosenberg R, Thompson JL, Bauer K, Mohr JP, Rosner B, Sciacca R, Barzegar S, Thornell B, Costigan T, Kistler JP. Thrombin generation in non-cardioembolic stroke subtypes: the Hemostatic System Activation Study. Neurology. 2004 Sep 14; 63(5):777-84.
    View in: PubMed
  46. Turpie AG, Bauer KA, Eriksson BI, Lassen MR. Superiority of fondaparinux over enoxaparin in preventing venous thromboembolism in major orthopedic surgery using different efficacy end points. Chest. 2004 Aug; 126(2):501-8.
    View in: PubMed
  47. Pantanowitz L, Bauer K, Tefs K, Schuster V, Balogh K, Pilch BZ, Adcock D, Cirovic C, Kocher O. Ligneous (pseudomembranous) inflammation involving the female genital tract associated with type-1 plasminogen deficiency. Int J Gynecol Pathol. 2004 Jul; 23(3):292-5.
    View in: PubMed
  48. Bauer KA. Fondaparinux: a new synthetic and selective inhibitor of Factor Xa. Best Pract Res Clin Haematol. 2004 Mar; 17(1):89-104.
    View in: PubMed
  49. Vossen CY, Hasstedt SJ, Rosendaal FR, Callas PW, Bauer KA, Broze GJ, Hoogendoorn H, Long GL, Scott BT, Bovill EG. Heritability of plasma concentrations of clotting factors and measures of a prethrombotic state in a protein C-deficient family. J Thromb Haemost. 2004 Feb; 2(2):242-7.
    View in: PubMed
  50. Turpie AG, Eriksson BI, Bauer KA, Lassen MR. New pentasaccharides for the prophylaxis of venous thromboembolism: clinical studies. Chest. 2003 Dec; 124(6 Suppl):371S-378S.
    View in: PubMed
  51. Bauer KA. New pentasaccharides for prophylaxis of deep vein thrombosis: pharmacology. Chest. 2003 Dec; 124(6 Suppl):364S-370S.
    View in: PubMed
  52. Turpie AG, Bauer KA, Eriksson BI, Lassen MR. Fondaparinux and prevention of venous thromboembolism after orthopaedic surgery. Lancet. 2003 Nov 8; 362(9395):1582-3.
    View in: PubMed
  53. Carew JA, Basso F, Miller GJ, Hawe E, Jackson AA, Humphries SE, Bauer KA. A functional haplotype in the 5' flanking region of the factor VII gene is associated with an increased risk of coronary heart disease. J Thromb Haemost. 2003 Oct; 1(10):2179-85.
    View in: PubMed
  54. Turpie AG, Eriksson BI, Lassen MR, Bauer KA. Fondaparinux, the first selective factor Xa inhibitor. Curr Opin Hematol. 2003 Sep; 10(5):327-32.
    View in: PubMed
  55. Turpie A, Bauer K, Eriksson B, Lassen M. Efficacy and safety of fondaparinux in major orthopedic surgery according to the timing of its first administration. Thromb Haemost. 2003 Aug; 90(2):364-6.
    View in: PubMed
  56. Ardissino D, Merlini PA, Bauer KA, Galvani M, Ottani F, Franchi F, Bertocchi F, Rosenberg RD, Mannucci PM. Coagulation activation and long-term outcome in acute coronary syndromes. Blood. 2003 Oct 15; 102(8):2731-5.
    View in: PubMed
  57. Bauer KA. Management of thrombophilia. J Thromb Haemost. 2003 Jul; 1(7):1429-34.
    View in: PubMed
  58. Carew JA, Jackson AA, Bauer KA. ARP1 interacts with the 5' flanking region of the coagulation factor VII gene. J Thromb Haemost. 2003 Jun; 1(6):1220-7.
    View in: PubMed
  59. Konkle BA, Bauer KA, Weinstein R, Greist A, Holmes HE, Bonfiglio J. Use of recombinant human antithrombin in patients with congenital antithrombin deficiency undergoing surgical procedures. Transfusion. 2003 Mar; 43(3):390-4.
    View in: PubMed
  60. Ridker PM, Goldhaber SZ, Danielson E, Rosenberg Y, Eby CS, Deitcher SR, Cushman M, Moll S, Kessler CM, Elliott CG, Paulson R, Wong T, Bauer KA, Schwartz BA, Miletich JP, Bounameaux H, Glynn RJ. Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. N Engl J Med. 2003 Apr 10; 348(15):1425-34.
    View in: PubMed
  61. Eriksson BI, Bauer KA, Lassen MR, Turpie AG. Influence of the duration of fondaparinux (Arixtra) prophylaxis in preventing venous thromboembolism following major orthopedic surgery. J Thromb Haemost. 2003 Feb; 1(2):383-4.
    View in: PubMed
  62. Press RD, Bauer KA, Kujovich JL, Heit JA. Clinical utility of factor V leiden (R506Q) testing for the diagnosis and management of thromboembolic disorders. Arch Pathol Lab Med. 2002 Nov; 126(11):1304-18.
    View in: PubMed
  63. Bauer KA. Fondaparinux: basic properties and efficacy and safety in venous thromboembolism prophylaxis. Am J Orthop (Belle Mead NJ). 2002 Nov; 31(11 Suppl):4-10.
    View in: PubMed
  64. Peyvandi F, De Cristofaro R, Akhavan S, Carew JA, Landolfi R, Bauer KA, Mannucci PM. Two naturally occurring mutations on FVII gene (S363I-W364C) altering intrinsic catalytic activity. Thromb Haemost. 2002 Nov; 88(5):750-5.
    View in: PubMed
  65. Moons AH, Peters RJ, Cate Ht, Bauer KA, Vlasuk GP, Büller HR, Levi M. Recombinant nematode anticoagulant protein c2, a novel inhibitor of tissue factor-factor VIIa activity, abrogates endotoxin-induced coagulation in chimpanzees. Thromb Haemost. 2002 Oct; 88(4):627-31.
    View in: PubMed
  66. Turpie AG, Bauer KA, Eriksson BI, Lassen MR. Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies. Arch Intern Med. 2002 Sep 9; 162(16):1833-40.
    View in: PubMed
  67. Bauer KA, Eriksson BI, Lassen MR, Turpie AG. Factor Xa inhibition in the prevention of venous thromboembolism and treatment of patients with venous thromboembolism. Curr Opin Pulm Med. 2002 Sep; 8(5):398-404.
    View in: PubMed
  68. Cella G, Randi ML, Sbarai A, Bauer KA, Barzega S, Rosenberg RD. Factor IX activation peptide and soluble selectins in patients with chronic myeloproliferative disorders. Haematologica. 2002 Jun; 87(6):671-2.
    View in: PubMed
  69. Bauer KA. Selective inhibition of coagulation factors: advances in antithrombotic therapy. Semin Thromb Hemost. 2002 Jun; 28 Suppl 2:15-24.
    View in: PubMed
  70. Hoffmann U, Harenberg J, Bauer K, Huhle G, Tolle AR, Feuring M, Christ M. Bioequivalence of subcutaneous and intravenous body-weight-independent high-dose low-molecular-weight heparin Certoparin on anti-Xa, Heptest, and tissue factor pathway inhibitor activity in volunteers. Blood Coagul Fibrinolysis. 2002 Jun; 13(4):289-96.
    View in: PubMed
  71. Bauer KA. Hormone replacement therapy and the factor V Leiden mutation. Arterioscler Thromb Vasc Biol. 2002 Jun 1; 22(6):879-80.
    View in: PubMed
  72. Turpie AG, Bauer KA, Eriksson BI, Lassen MR. Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery: a randomised double-blind trial. Lancet. 2002 May 18; 359(9319):1721-6.
    View in: PubMed
  73. Lassen MR, Bauer KA, Eriksson BI, Turpie AG. Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: a randomised double-blind comparison. Lancet. 2002 May 18; 359(9319):1715-20.
    View in: PubMed
  74. Miller GJ, Bauer KA, Howarth DJ, Mitchell JP, Cooper JA. Does inflammatory proteolytic activity contribute to the increased factor IX activation peptide in men at high risk of coronary heart disease? A preliminary study. Thromb Haemost. 2002 Mar; 87(3):415-20.
    View in: PubMed
  75. Bauer KA, Hawkins DW, Peters PC, Petitou M, Herbert JM, van Boeckel CA, Meuleman DG. Fondaparinux, a synthetic pentasaccharide: the first in a new class of antithrombotic agents - the selective factor Xa inhibitors. Cardiovasc Drug Rev. 2002; 20(1):37-52.
    View in: PubMed
  76. Turpie AG, Eriksson BI, Lassen MR, Bauer KA. A meta-analysis of fondaparinux versus enoxaparin in the prevention of venous thromboembolism after major orthopaedic surgery. J South Orthop Assoc. 2002; 11(4):182-8.
    View in: PubMed
  77. Bauer KA, Rosendaal FR, Heit JA. Hypercoagulability: too many tests, too much conflicting data. Hematology Am Soc Hematol Educ Program. 2002; 353-68.
    View in: PubMed
  78. Bauer KA, Eriksson BI, Lassen MR, Turpie AG. A new antithrombotic strategy, the selective inhibition of coagulation factors, and its importance to the orthopedic specialist. J South Orthop Assoc. 2002; 11(4):197-202.
    View in: PubMed
  79. Gilchrist A, Solomon N, Erickson D, Sikand A, Bauer KA, Kruskall MS, Kocher O. Automated detection of the G20210A prothrombin mutation using the LCx microparticle enzyme immunoassay. Clin Chim Acta. 2001 Dec; 314(1-2):249-54.
    View in: PubMed
  80. Bauer KA. Fondaparinux sodium: a selective inhibitor of factor Xa. Am J Health Syst Pharm. 2001 Nov 1; 58 Suppl 2:S14-7.
    View in: PubMed
  81. Ardissino D, Merlini PA, Bauer KA, Bramucci E, Ferrario M, Coppola R, Fetiveau R, Lucreziotti S, Rosenberg RD, Mannucci PM. Thrombogenic potential of human coronary atherosclerotic plaques. Blood. 2001 Nov 1; 98(9):2726-9.
    View in: PubMed
  82. Bauer KA, Eriksson BI, Lassen MR, Turpie AG. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery. N Engl J Med. 2001 Nov 1; 345(18):1305-10.
    View in: PubMed
  83. Eriksson BI, Bauer KA, Lassen MR, Turpie AG. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery. N Engl J Med. 2001 Nov 1; 345(18):1298-304.
    View in: PubMed
  84. Bauer KA. The thrombophilias: well-defined risk factors with uncertain therapeutic implications. Ann Intern Med. 2001 Sep 4; 135(5):367-73.
    View in: PubMed
  85. Merlini PA, Rossi ML, Bauer KA. Hemostatic markers and prognosis in ischemic heart disease. Ital Heart J. 2001 Jul; 2(7):499-501.
    View in: PubMed
  86. Friederich PW, Levi M, Bauer KA, Vlasuk GP, Rote WE, Breederveld D, Keller T, Spataro M, Barzegar S, Büller HR. Ability of recombinant factor VIIa to generate thrombin during inhibition of tissue factor in human subjects. Circulation. 2001 May 29; 103(21):2555-9.
    View in: PubMed
  87. Bauer KA. Conventional fibrinolytic assays for the evaluation of patients with venous thrombosis: don't bother. Thromb Haemost. 2001 Mar; 85(3):377-8.
    View in: PubMed
  88. Peyvandi F, Carew JA, Perry DJ, Hunault M, Khanduri U, Perkins SJ, Mannucci PM, Bauer KA. Abnormal secretion and function of recombinant human factor VII as the result of modification to a calcium binding site caused by a 15-base pair insertion in the F7 gene. Blood. 2001 Feb 15; 97(4):960-5.
    View in: PubMed
  89. Daniel V, Huber W, Bauer K, Suesal C, Mytilineos J, Melk A, Conradt C, Opelz G. Association of elevated blood levels of pentachlorophenol (PCP) with cellular and humoral immunodeficiencies. Arch Environ Health. 2001 Jan-Feb; 56(1):77-83.
    View in: PubMed
  90. Carew JA, Pollak ES, Lopaciuk S, Bauer KA. A new mutation in the HNF4 binding region of the factor VII promoter in a patient with severe factor VII deficiency. Blood. 2000 Dec 15; 96(13):4370-2.
    View in: PubMed
  91. Heuer H, Schäfer MK, O'Donnell D, Walker P, Bauer K. Expression of thyrotropin-releasing hormone receptor 2 (TRH-R2) in the central nervous system of rats. J Comp Neurol. 2000 Dec 11; 428(2):319-36.
    View in: PubMed
  92. Cooper JA, Miller GJ, Bauer KA, Morrissey JH, Meade TW, Howarth DJ, Barzegar S, Mitchell JP, Rosenberg RD. Comparison of novel hemostatic factors and conventional risk factors for prediction of coronary heart disease. Circulation. 2000 Dec 5; 102(23):2816-22.
    View in: PubMed
  93. Minnema MC, Peters RJ, de Winter R, Lubbers YP, Barzegar S, Bauer KA, Rosenberg RD, Hack CE, ten Cate H. Activation of clotting factors XI and IX in patients with acute myocardial infarction. Arterioscler Thromb Vasc Biol. 2000 Nov; 20(11):2489-93.
    View in: PubMed
  94. Bauer KA, Humphries S, Smillie B, Li L, Cooper JA, Barzegar S, Rosenberg RD, Miller GJ. Prothrombin activation is increased among asymptomatic carriers of the prothrombin G20210A and factor V Arg506Gln mutations. Thromb Haemost. 2000 Sep; 84(3):396-400.
    View in: PubMed
  95. Merlini PA, Ardissino D, Rosenberg RD, Colombi E, Agricola P, Oltrona L, Ottani F, Galvani M, Bauer KA, Bottasso B, Bertocchi F, Mannucci PM. In vivo thrombin generation and activity during and after intravenous infusion of heparin or recombinant hirudin in patients with unstable angina pectoris. Arterioscler Thromb Vasc Biol. 2000 Sep; 20(9):2162-6.
    View in: PubMed
  96. Bovill EG, Hasstedt SJ, Callas PW, Valliere JE, Scott BT, Bauer KA, Long GL. The G20210A prothrombin polymorphism is not associated with increased thromboembolic risk in a large protein C deficient kindred. Thromb Haemost. 2000 Mar; 83(3):366-70.
    View in: PubMed
  97. Wilson WH, Sorbara L, Figg WD, Mont EK, Sausville E, Warren KE, Balis FM, Bauer K, Raffeld M, Senderowicz AM, Monks A. Modulation of clinical drug resistance in a B cell lymphoma patient by the protein kinase inhibitor 7-hydroxystaurosporine: presentation of a novel therapeutic paradigm. Clin Cancer Res. 2000 Feb; 6(2):415-21.
    View in: PubMed
  98. Hunault M, Bauer KA. Recombinant factor VIIa for the treatment of congenital factor VII deficiency. Semin Thromb Hemost. 2000; 26(4):401-5.
    View in: PubMed
  99. Bauer KA. Activation markers of coagulation. Baillieres Best Pract Res Clin Haematol. 1999 Sep; 12(3):387-406.
    View in: PubMed
  100. Hunault M, Arbini AA, Carew JA, Bauer KA. Mechanism underlying factor VII deficiency in Jewish populations with the Ala244Val mutation. Br J Haematol. 1999 Jun; 105(4):1101-8.
    View in: PubMed
  101. Xu X, Bauer KA, Griffin JH. Two multiplex PCR-based DNA assays for the thrombosis risk factors prothrombin G20210A and coagulation factor V G1691A polymorphisms. Thromb Res. 1999 Mar 15; 93(6):265-9.
    View in: PubMed
  102. Wulf GM, Van Deerlin VM, Leonard DG, Bauer KA. Thrombosis in a patient with combined homozygosity for the factor V Leiden mutation and a mutation in the 3'-untranslated region of the prothrombin gene. Blood Coagul Fibrinolysis. 1999 Mar; 10(2):107-10.
    View in: PubMed
  103. Hunault M, Arbini AA, Carew JA, Peyvandi F, Bauer KA. Characterization of two naturally occurring mutations in the second epidermal growth factor-like domain of factor VII. Blood. 1999 Feb 15; 93(4):1237-44.
    View in: PubMed
  104. Hunault M, Marsh-Scott C, Jou C, Marshall R, Scheffel C, Fiore LD, Bauer KA, Mitchell MJ. Automated detection of the factor V Leiden mutation using the LCx microparticle enzyme immunoassay. Clin Chem. 1999 Jan; 45(1):41-6.
    View in: PubMed
  105. Carew JA, Pollak ES, High KA, Bauer KA. Severe factor VII deficiency due to a mutation disrupting an Sp1 binding site in the factor VII promoter. Blood. 1998 Sep 1; 92(5):1639-45.
    View in: PubMed
  106. Miller GJ, Bauer KA, Cooper JA, Rosenberg RD. Activation of the coagulant pathway in cigarette smokers. Thromb Haemost. 1998 Mar; 79(3):549-53.
    View in: PubMed
  107. Hunault M, Arbini AA, Lopaciuk S, Carew JA, Bauer KA. The Arg353Gln polymorphism reduces the level of coagulation factor VII. In vivo and in vitro studies. Arterioscler Thromb Vasc Biol. 1997 Nov; 17(11):2825-9.
    View in: PubMed
  108. Merlini PA, Ardissino D, Bauer KA, Oltrona L, Pezzano A, Bottasso B, Rosenberg RD, Mannucci PM. Persistent thrombin generation during heparin therapy in patients with acute coronary syndromes. Arterioscler Thromb Vasc Biol. 1997 Jul; 17(7):1325-30.
    View in: PubMed
  109. Bauer KA. Activation of the factor VII-tissue factor pathway. Thromb Haemost. 1997 Jul; 78(1):108-11.
    View in: PubMed
  110. Arbini AA, Pollak ES, Bayleran JK, High KA, Bauer KA. Severe factor VII deficiency due to a mutation disrupting a hepatocyte nuclear factor 4 binding site in the factor VII promoter. Blood. 1997 Jan 1; 89(1):176-82.
    View in: PubMed
  111. Lane DA, Mannucci PM, Bauer KA, Bertina RM, Bochkov NP, Boulyjenkov V, Chandy M, Dahlbäck B, Ginter EK, Miletich JP, Rosendaal FR, Seligsohn U. Inherited thrombophilia: Part 2. Thromb Haemost. 1996 Dec; 76(6):824-34.
    View in: PubMed
  112. Silveira A, Karpe F, Johnsson H, Bauer KA, Hamsten A. In vivo demonstration in humans that large postprandial triglyceride-rich lipoproteins activate coagulation factor VII through the intrinsic coagulation pathway. Arterioscler Thromb Vasc Biol. 1996 Nov; 16(11):1333-9.
    View in: PubMed
  113. Lane DA, Mannucci PM, Bauer KA, Bertina RM, Bochkov NP, Boulyjenkov V, Chandy M, Dahlbäck B, Ginter EK, Miletich JP, Rosendaal FR, Seligsohn U. Inherited thrombophilia: Part 1. Thromb Haemost. 1996 Nov; 76(5):651-62.
    View in: PubMed
  114. Arbini AA, Mannucci M, Bauer KA. A Thr359Met mutation in factor VII of a patient with a hereditary deficiency causes defective secretion of the molecule. Blood. 1996 Jun 15; 87(12):5085-94.
    View in: PubMed
  115. Miller GJ, Bauer KA, Barzegar S, Cooper JA, Rosenberg RD. Increased activation of the haemostatic system in men at high risk of fatal coronary heart disease. Thromb Haemost. 1996 May; 75(5):767-71.
    View in: PubMed
  116. ten Cate H, Biemond BJ, Levi M, Wuillemin WA, Bauer KA, Barzegar S, Buller HR, Hack CE, ten Cate JW, Rosenberg RD. Factor XIa induced activation of the intrinsic cascade in vivo. Thromb Haemost. 1996 Mar; 75(3):445-9.
    View in: PubMed
  117. van Boven HH, Reitsma PH, Rosendaal FR, Bayston TA, Chowdhury V, Bauer KA, Scharrer I, Conard J, Lane DA. Factor V Leiden (FV R506Q) in families with inherited antithrombin deficiency. Thromb Haemost. 1996 Mar; 75(3):417-21.
    View in: PubMed
  118. Bauer KA, Eichinger S, Mannucci PM, Rosenberg RD. Determinants of coagulation activation in humans. Haemostasis. 1996; 26 Suppl 1:72-5.
    View in: PubMed
  119. Bauer KA. Treatment of factor VII deficiency with recombinant factor VIIa. Haemostasis. 1996; 26 Suppl 1:155-8.
    View in: PubMed
  120. Cohen LJ, McWilliams NB, Neuberg R, Zinkham W, Bauer K, Gribble TJ, Glowalla MB, Borson R, Phillips MD, Kunschak M. Prophylaxis and therapy with factor VII concentrate (human) immuno, vapor heated in patients with congenital factor VII deficiency: a summary of case reports. Am J Hematol. 1995 Dec; 50(4):269-76.
    View in: PubMed
  121. Arbini AA, Mannucci PM, Bauer KA. Low prevalence of the factor V Leiden mutation among "severe" hemophiliacs with a "milder" bleeding diathesis. Thromb Haemost. 1995 Nov; 74(5):1255-8.
    View in: PubMed
  122. Merlini PA, Ardissino D, Bauer KA, Oltrona L, Spinola A, Diotallevi P, Rosenberg RD, Mannucci PM. Activation of the hemostatic mechanism during thrombolysis in patients with unstable angina pectoris. Blood. 1995 Nov 1; 86(9):3327-32.
    View in: PubMed
  123. Eichinger S, Mannucci PM, Tradati F, Arbini AA, Rosenberg RD, Bauer KA. Determinants of plasma factor VIIa levels in humans. Blood. 1995 Oct 15; 86(8):3021-5.
    View in: PubMed
  124. Bauer K, Müller H, Schedel M, Truscheit E, Schnabel E. Novel microbial inhibitors of ACE. Isolation and characterization. Int J Pept Protein Res. 1995 Sep-Oct; 46(3-4):205-8.
    View in: PubMed
  125. Bauer K, Kurz J, Rosentreter H, Schedel M, Weber B, Wünsche C, Schnabel E. Structures of BAY o 6997 and BAY q 1313 microbial ACE inhibitors. Int J Pept Protein Res. 1995 Sep-Oct; 46(3-4):302-5.
    View in: PubMed
  126. Váradi K, Moritz B, Lang H, Bauer K, Preston E, Peake I, Rivard GE, Keil B, Schwarz HP. A chromogenic assay for activated protein C resistance. Br J Haematol. 1995 Aug; 90(4):884-91.
    View in: PubMed
  127. Bauer KA. Management of patients with hereditary defects predisposing to thrombosis including pregnant women. Thromb Haemost. 1995 Jul; 74(1):94-100.
    View in: PubMed
  128. Mari D, Mannucci PM, Coppola R, Bottasso B, Bauer KA, Rosenberg RD. Hypercoagulability in centenarians: the paradox of successful aging. Blood. 1995 Jun 1; 85(11):3144-9.
    View in: PubMed
  129. Schmaier AH, Dahl LD, Hasan AA, Cines DB, Bauer KA, Van Nostrand WE. Factor IXa inhibition by protease nexin-2/amyloid beta-protein precursor on phospholipid vesicles and cell membranes. Biochemistry. 1995 Jan 31; 34(4):1171-8.
    View in: PubMed
  130. Merlini PA, Bauer KA, Oltrona L, Ardissino D, Spinola A, Cattaneo M, Broccolino M, Mannucci PM, Rosenberg RD. Thrombin generation and activity during thrombolysis and concomitant heparin therapy in patients with acute myocardial infarction. J Am Coll Cardiol. 1995 Jan; 25(1):203-9.
    View in: PubMed
  131. Miller GJ, Bauer KA, Barzegar S, Foley AJ, Mitchell JP, Cooper JA, Rosenberg RD. The effects of quality and timing of venepuncture on markers of blood coagulation in healthy middle-aged men. Thromb Haemost. 1995 Jan; 73(1):82-6.
    View in: PubMed
  132. Greengard JS, Eichinger S, Griffin JH, Bauer KA. Brief report: variability of thrombosis among homozygous siblings with resistance to activated protein C due to an Arg-->Gln mutation in the gene for factor V. N Engl J Med. 1994 Dec 8; 331(23):1559-62.
    View in: PubMed
  133. Arbini AA, Bodkin D, Lopaciuk S, Bauer KA. Molecular analysis of Polish patients with factor VII deficiency. Blood. 1994 Oct 1; 84(7):2214-20.
    View in: PubMed
  134. Bauer KA. New markers for in vivo coagulation. Curr Opin Hematol. 1994 Sep; 1(5):341-6.
    View in: PubMed
  135. Bauer KA, Rosenberg RD. Activation markers of coagulation. Baillieres Clin Haematol. 1994 Sep; 7(3):523-40.
    View in: PubMed
  136. Mannucci PM, Bauer KA, Santagostino E, Faioni E, Barzegar S, Coppola R, Rosenberg RD. Activation of the coagulation cascade after infusion of a factor XI concentrate in congenitally deficient patients. Blood. 1994 Aug 15; 84(4):1314-9.
    View in: PubMed
  137. Merlini PA, Bauer KA, Oltrona L, Ardissino D, Cattaneo M, Belli C, Mannucci PM, Rosenberg RD. Persistent activation of coagulation mechanism in unstable angina and myocardial infarction. Circulation. 1994 Jul; 90(1):61-8.
    View in: PubMed
  138. Santagostino E, Mannucci PM, Gringeri A, Tagariello G, Baudo F, Bauer KA, Rosenberg RD. Markers of hypercoagulability in patients with hemophilia B given repeated, large doses of factor IX concentrates during and after surgery. Thromb Haemost. 1994 Jun; 71(6):737-40.
    View in: PubMed
  139. Bauer KA. Hypercoagulability--a new cofactor in the protein C anticoagulant pathway. N Engl J Med. 1994 Feb 24; 330(8):566-7.
    View in: PubMed
  140. Levi M, ten Cate H, Bauer KA, van der Poll T, Edgington TS, Büller HR, van Deventer SJ, Hack CE, ten Cate JW, Rosenberg RD. Inhibition of endotoxin-induced activation of coagulation and fibrinolysis by pentoxifylline or by a monoclonal anti-tissue factor antibody in chimpanzees. J Clin Invest. 1994 Jan; 93(1):114-20.
    View in: PubMed
  141. Kistler JP, Singer DE, Millenson MM, Bauer KA, Gress DR, Barzegar S, Hughes RA, Sheehan MA, Maraventano SW, Oertel LB, et al. Effect of low-intensity warfarin anticoagulation on level of activity of the hemostatic system in patients with atrial fibrillation. BAATAF Investigators. Stroke. 1993 Sep; 24(9):1360-5.
    View in: PubMed
  142. ten Cate H, Bauer KA, Levi M, Edgington TS, Sublett RD, Barzegar S, Kass BL, Rosenberg RD. The activation of factor X and prothrombin by recombinant factor VIIa in vivo is mediated by tissue factor. J Clin Invest. 1993 Sep; 92(3):1207-12.
    View in: PubMed
  143. Conard J, Bauer KA, Gruber A, Griffin JH, Schwarz HP, Horellou MH, Samama MM, Rosenberg RD. Normalization of markers of coagulation activation with a purified protein C concentrate in adults with homozygous protein C deficiency. Blood. 1993 Aug 15; 82(4):1159-64.
    View in: PubMed
  144. Chowdhury V, Olds RJ, Lane DA, Conard J, Pabinger I, Ryan K, Bauer KA, Bhavnani M, Abildgaard U, Finazzi G, et al. Identification of nine novel mutations in type I antithrombin deficiency by heteroduplex screening. Br J Haematol. 1993 Aug; 84(4):656-61.
    View in: PubMed
  145. Schramm W, Spannagl M, Bauer KA, Rosenberg RD, Birkner B, Linnau Y, Schwarz HP. Treatment of coumarin-induced skin necrosis with a monoclonal antibody purified protein C concentrate. Arch Dermatol. 1993 Jun; 129(6):753-6.
    View in: PubMed
  146. Rosenberg RD, Bauer KA. Prothrombin activation fragment assay. Clin Chem. 1993 Apr; 39(4):559-60.
    View in: PubMed
  147. Bauer K, Dietersdorfer F, Sertl K, Kaik B, Kaik G. Pharmacodynamic effects of inhaled dry powder formulations of fenoterol and colforsin in asthma. Clin Pharmacol Ther. 1993 Jan; 53(1):76-83.
    View in: PubMed
  148. Bauer KA. Laboratory markers of coagulation activation. Arch Pathol Lab Med. 1993 Jan; 117(1):71-7.
    View in: PubMed
  149. Caine YG, Bauer KA, Barzegar S, ten Cate H, Sacks FM, Walsh BW, Schiff I, Rosenberg RD. Coagulation activation following estrogen administration to postmenopausal women. Thromb Haemost. 1992 Oct 5; 68(4):392-5.
    View in: PubMed
  150. Rosenberg RD, Bauer KA. Does a prethrombotic state exist? If so, what is it? Am J Clin Nutr. 1992 Oct; 56(4 Suppl):787S-788S.
    View in: PubMed
  151. Wilkes HC, Meade TW, Barzegar S, Foley AJ, Hughes LO, Bauer KA, Rosenberg RD, Miller GJ. Gemfibrozil reduces plasma prothrombin fragment F1 + 2 concentration, a marker of coagulability, in patients with coronary heart disease. Thromb Haemost. 1992 May 4; 67(5):503-6.
    View in: PubMed
  152. Bauer KA, Mannucci PM, Gringeri A, Tradati F, Barzegar S, Kass BL, ten Cate H, Kestin AS, Brettler DB, Rosenberg RD. Factor IXa-factor VIIIa-cell surface complex does not contribute to the basal activation of the coagulation mechanism in vivo. Blood. 1992 Apr 15; 79(8):2039-47.
    View in: PubMed
  153. Millenson MM, Bauer KA, Kistler JP, Barzegar S, Tulin L, Rosenberg RD. Monitoring "mini-intensity" anticoagulation with warfarin: comparison of the prothrombin time using a sensitive thromboplastin with prothrombin fragment F1+2 levels. Blood. 1992 Apr 15; 79(8):2034-8.
    View in: PubMed
  154. Pittman DD, Millenson M, Marquette K, Bauer K, Kaufman RJ. A2 domain of human recombinant-derived factor VIII is required for procoagulant activity but not for thrombin cleavage. Blood. 1992 Jan 15; 79(2):389-97.
    View in: PubMed
  155. Ballen KK, Canoso R, Seiler M, Neish A, Bauer KA. Neuroendocrine carcinoma in a patient with hairy cell leukemia: a case report. Med Pediatr Oncol. 1992; 20(4):349-51.
    View in: PubMed
  156. Mannucci PM, Bauer KA, Gringeri A, Barzegar S, Santagostino E, Tradati FC, Rosenberg RD. No activation of the common pathway of the coagulation cascade after a highly purified factor IX concentrate. Br J Haematol. 1991 Dec; 79(4):606-11.
    View in: PubMed
  157. Miller GJ, Wilkes HC, Meade TW, Bauer KA, Barzegar S, Rosenberg RD. Haemostatic changes that constitute the hypercoagulable state. Lancet. 1991 Oct 26; 338(8774):1079.
    View in: PubMed
  158. Lee MH, Kaczmarek E, Chin DT, Oda A, McIntosh S, Bauer KA, Clyne LP, McDonagh J. Fibrinogen Ledyard (A alpha Arg16----Cys): biochemical and physiologic characterization. Blood. 1991 Oct 1; 78(7):1744-52.
    View in: PubMed
  159. Bauer KA, Barzegar S, Rosenberg RD. Influence of anticoagulants used for blood collection on plasma prothrombin fragment F1 + 2 measurements. Thromb Res. 1991 Sep 15; 63(6):617-28.
    View in: PubMed
  160. Kaik B, Bauer K, Bröll H. Double-blind randomized clinical trial on imidazole salicylate vs ibuprofen in osteoarthritis. Int J Clin Pharmacol Ther Toxicol. 1991 May; 29(5):173-7.
    View in: PubMed
  161. Bauer KA, Rosenberg RD. Role of antithrombin III as a regulator of in vivo coagulation. Semin Hematol. 1991 Jan; 28(1):10-8.
    View in: PubMed
  162. Mannucci PM, Bauer KA, Gringeri A, Barzegar S, Bottasso B, Simoni L, Rosenberg RD. Thrombin generation is not increased in the blood of hemophilia B patients after the infusion of a purified factor IX concentrate. Blood. 1990 Dec 15; 76(12):2540-5.
    View in: PubMed
  163. van Hinsbergh VW, Bauer KA, Kooistra T, Kluft C, Dooijewaard G, Sherman ML, Nieuwenhuizen W. Progress of fibrinolysis during tumor necrosis factor infusions in humans. Concomitant increase in tissue-type plasminogen activator, plasminogen activator inhibitor type-1, and fibrin(ogen) degradation products. Blood. 1990 Dec 1; 76(11):2284-9.
    View in: PubMed
  164. Hammond MD, Bauer KA, Sharp JT, Rocha RD. Respiratory muscle strength in congestive heart failure. Chest. 1990 Nov; 98(5):1091-4.
    View in: PubMed
  165. Bauer KA, Kass BL, ten Cate H, Hawiger JJ, Rosenberg RD. Factor IX is activated in vivo by the tissue factor mechanism. Blood. 1990 Aug 15; 76(4):731-6.
    View in: PubMed
  166. van der Poll T, Büller HR, ten Cate H, Wortel CH, Bauer KA, van Deventer SJ, Hack CE, Sauerwein HP, Rosenberg RD, ten Cate JW. Activation of coagulation after administration of tumor necrosis factor to normal subjects. N Engl J Med. 1990 Jun 7; 322(23):1622-7.
    View in: PubMed
  167. Bauer KA, Kass BL, ten Cate H, Bednarek MA, Hawiger JJ, Rosenberg RD. Detection of factor X activation in humans. Blood. 1989 Nov 1; 74(6):2007-15.
    View in: PubMed
  168. Bauer KA, Conway EM, Bach R, Konigsberg WH, Griffin JD, Demetri G. Tissue factor gene expression in acute myeloblastic leukemia. Thromb Res. 1989 Nov 1; 56(3):425-30.
    View in: PubMed
  169. Schwartz RS, Bauer KA, Rosenberg RD, Kavanaugh EJ, Davies DC, Bogdanoff DA. Clinical experience with antithrombin III concentrate in treatment of congenital and acquired deficiency of antithrombin. The Antithrombin III Study Group. Am J Med. 1989 Sep 11; 87(3B):53S-60S.
    View in: PubMed
  170. Bauer KA, Rosenberg RD. Congenital antithrombin III deficiency: insights into the pathogenesis of the hypercoagulable state and its management using markers of hemostatic system activation. Am J Med. 1989 Sep 11; 87(3B):39S-43S.
    View in: PubMed
  171. Walker PA, Bauer KA, McDonagh J. A simple, automated functional assay for protein C. Am J Clin Pathol. 1989 Aug; 92(2):210-3.
    View in: PubMed
  172. Bauer KA, ten Cate H, Barzegar S, Spriggs DR, Sherman ML, Rosenberg RD. Tumor necrosis factor infusions have a procoagulant effect on the hemostatic mechanism of humans. Blood. 1989 Jul; 74(1):165-72.
    View in: PubMed
  173. Erdjument H, Lane DA, Panico M, Di Marzo V, Morris HR, Bauer K, Rosenberg RD. Antithrombin Chicago, amino acid substitution of arginine 393 to histidine. Thromb Res. 1989 Jun 15; 54(6):613-9.
    View in: PubMed
  174. Bovill EG, Bauer KA, Dickerman JD, Callas P, West B. The clinical spectrum of heterozygous protein C deficiency in a large New England kindred. Blood. 1989 Feb 15; 73(3):712-7.
    View in: PubMed
  175. Bauer KA, Broekmans AW, Bertina RM, Conard J, Horellou MH, Samama MM, Rosenberg RD. Hemostatic enzyme generation in the blood of patients with hereditary protein C deficiency. Blood. 1988 May; 71(5):1418-26.
    View in: PubMed
  176. Vukovich TC, Knöbl PN, Bauer K, Tragl KH, Deutsch E. Quantitative determination of human protein C. Evaluation of a "fast" functional assay in comparison to a "traditional" functional and an immunological assay. Thromb Res. 1988 Jan 15; 49(2):169-79.
    View in: PubMed
  177. Conway EM, Bauer KA, Barzegar S, Rosenberg RD. Suppression of hemostatic system activation by oral anticoagulants in the blood of patients with thrombotic diatheses. J Clin Invest. 1987 Dec; 80(6):1535-44.
    View in: PubMed
  178. Bauer KA, Weiss LM, Sparrow D, Vokonas PS, Rosenberg RD. Aging-associated changes in indices of thrombin generation and protein C activation in humans. Normative Aging Study. J Clin Invest. 1987 Dec; 80(6):1527-34.
    View in: PubMed
  179. Conway EM, Lau HK, Bauer KA, Rosenberg RD. Development of a radioimmunoassay for quantitating prethrombin 2 in human plasma. J Lab Clin Med. 1987 Nov; 110(5):567-75.
    View in: PubMed
  180. Bauer KA, Rosenberg RD. The pathophysiology of the prethrombotic state in humans: insights gained from studies using markers of hemostatic system activation. Blood. 1987 Aug; 70(2):343-50.
    View in: PubMed
  181. Sala N, Borrell M, Bauer KA, Viganò-D'Angelo S, Fontcuberta J, Félez J, Rutllant ML. Dysfunctional activated protein C (PC Cádiz) in a patient with thrombotic disease. Thromb Haemost. 1987 Apr 7; 57(2):183-6.
    View in: PubMed
  182. Rosenberg RD, Bauer KA. Thrombosis in inherited deficiencies of antithrombin, protein C, and protein S. Hum Pathol. 1987 Mar; 18(3):253-62.
    View in: PubMed
  183. Rosenberg RD, Bauer KA. New insights into hypercoagulable states. Hosp Pract (Off Ed). 1986 Mar 15; 21(3):131-8, 143, 147.
    View in: PubMed
  184. Weinstein MJ, Chute LE, Schmitt GW, Hamburger RH, Bauer KA, Troll JH, Janson P, Deykin D. Abnormal factor VIII coagulant antigen in patients with renal dysfunction and in those with disseminated intravascular coagulation. J Clin Invest. 1985 Oct; 76(4):1406-11.
    View in: PubMed
  185. Bauer KA, Goodman TL, Kass BL, Rosenberg RD. Elevated factor Xa activity in the blood of asymptomatic patients with congenital antithrombin deficiency. J Clin Invest. 1985 Aug; 76(2):826-36.
    View in: PubMed
  186. Lindon JN, Salzman EW, Merrill EW, Dincer AK, Labarre D, Bauer KA, Rosenberg RR. Catalytic activity and platelet reactivity of heparin covalently bonded to surfaces. J Lab Clin Med. 1985 Feb; 105(2):219-26.
    View in: PubMed
  187. Rosenberg RD, Bauer KA, Marcum JA. Protease inhibitors of human plasma. Antithrombin-III. "The heparin-antithrombin system". J Med. 1985; 16(1-3):351-416.
    View in: PubMed
  188. Bauer KA. The role of the laboratory in preventing and diagnosing arterial or veinal thrombotic accidents, and in monitoring their treatment. Ann Biol Clin (Paris). 1985; 43(4):451-4.
    View in: PubMed
  189. Bauer KA, Kass BL, Beeler DL, Rosenberg RD. Detection of protein C activation in humans. J Clin Invest. 1984 Dec; 74(6):2033-41.
    View in: PubMed
  190. Bauer KA, Rosenberg RD. Thrombin generation in acute promyelocytic leukemia. Blood. 1984 Oct; 64(4):791-6.
    View in: PubMed
  191. Bauer KA, Ashenhurst JB, Chediak J, Rosenberg RD. Antithrombin "Chicago": a functionally abnormal molecule with increased heparin affinity causing familial thrombophilia. Blood. 1983 Dec; 62(6):1242-50.
    View in: PubMed
  192. Prochownik EV, Antonarakis S, Bauer KA, Rosenberg RD, Fearon ER, Orkin SH. Molecular heterogeneity of inherited antithrombin III deficiency. N Engl J Med. 1983 Jun 30; 308(26):1549-52.
    View in: PubMed
  193. Bauer KA, Teitel JM, Rosenberg RD. L-asparaginase induced antithrombin III deficiency: evidence against the production of a hypercoagulable state. Thromb Res. 1983 Feb 15; 29(4):437-42.
    View in: PubMed
  194. Stead NW, Bauer KA, Kinney TR, Lewis JG, Campbell EE, Shifman MA, Rosenberg RD, Pizzo SV. Venous thrombosis in a family with defective release of vascular plasminogen activator and elevated plasma factor VIII/von Willebrand's factor. Am J Med. 1983 Jan; 74(1):33-9.
    View in: PubMed
  195. Teitel JM, Bauer KA, Lau HK, Rosenberg RD. Studies of the prothrombin activation pathway utilizing radioimmunoassays for the F2/F1 + 2 fragment and thrombin--antithrombin complex. Blood. 1982 May; 59(5):1086-97.
    View in: PubMed
  196. Bauer KA, Siegler M, Lindheimer MA. Polymyositis complicating pregnancy. Arch Intern Med. 1979 Apr; 139(4):449.
    View in: PubMed
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact Human Resources at faculty_serviceshms.harvard.edu.
Bauer's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts
See all (629) concept(s)
_
Co-Authors
See all (41) people
_
Similar People
See all (60) people
_
Same Department
Search Department
Physical Neighbors
_